Abstract
In classic infantile-onset Pompe disease (IOPD), symptoms start early in life, and there is a fatal outcome if the disease remains untreated.1 Enzyme replacement therapy (ERT) with recombinant human GAA remains the single treatment favouring a prolonged life expectancy.2–4 To our knowledge, there have been no studies investigating the role of an early and intensive global rehabilitation programme in IPOD infants treated with ERT. We present an 18-month neurorehabilitation follow-up in a child.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
